Sun-Novo(SH:688621)2025-04-24 14:00Financial Performance - The company's operating revenue for Q1 2025 was CNY 230,839,657.82, representing a decrease of 8.49% compared to CNY 252,264,171.81 in the same period last year[6]. - Net profit attributable to shareholders decreased by 59.34% to CNY 29,578,574.65 from CNY 72,753,830.32 year-on-year[6]. - The net profit after deducting non-recurring gains and losses fell by 69.67% to CNY 20,204,780.22 compared to CNY 66,620,135.97 in the previous year[6]. - Total operating revenue for Q1 2025 was ¥230,839,657.82, a decrease of 8.5% compared to ¥252,264,171.81 in Q1 2024[20]. - Net profit for Q1 2025 was ¥27,351,759.45, down 60.2% from ¥68,742,684.61 in Q1 2024[21]. - Operating profit for Q1 2025 was ¥23,441,916.35, a decline of 68.5% compared to ¥74,431,541.98 in Q1 2024[21]. - Earnings per share for Q1 2025 was ¥0.27, down from ¥0.66 in Q1 2024[22]. Cash Flow - The net cash flow from operating activities increased by 66.63% to CNY 10,331,866.61, up from CNY 6,200,449.68 in the same period last year[6]. - Cash inflow from operating activities totaled $246,173,706.79, an increase from $214,471,499.10 in the previous period, reflecting a growth of approximately 14.8%[24]. - Net cash outflow from investing activities was -$44,183,885.87, an improvement compared to -$123,665,060.39 in the prior period, indicating a reduction in cash outflow by about 64.3%[25]. - Cash inflow from financing activities amounted to $267,713,950.00, up from $213,900,000.00, representing an increase of approximately 25.2%[25]. - The net cash flow from financing activities was $58,866,217.08, a decrease from $145,707,166.54, showing a decline of about 59.6%[25]. - The net increase in cash and cash equivalents was $25,014,197.82, compared to $28,242,555.83 in the previous period, reflecting a decrease of approximately 11.4%[25]. - Total cash outflow for operating activities was $235,841,840.18, compared to $208,271,049.42, marking an increase of approximately 13.3%[24]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,135,237,784.73, reflecting a 7.44% increase from CNY 1,987,303,846.03 at the end of the previous year[7]. - Current assets reached RMB 1,657,336,780.13, up from RMB 1,514,492,436.13, indicating an increase of about 9.43%[16]. - The company's short-term borrowings increased significantly to RMB 486,131,515.20 from RMB 309,391,261.65, representing a growth of around 56.9%[17]. - The total liabilities reached RMB 1,013,418,236.48, up from RMB 778,563,811.73, reflecting an increase of approximately 30.1%[17]. - Total liabilities increased to ¥1,105,234,199.72 in the latest reporting period, up from ¥884,652,040.88[18]. - Total equity decreased to ¥1,030,003,585.01 from ¥1,102,651,805.15[18]. - Long-term borrowings decreased to ¥57,600,000.00 from ¥67,200,000.00[18]. Research and Development - Research and development expenses totaled CNY 37,729,451.82, accounting for 16.34% of operating revenue, an increase from 13.86% year-on-year[6]. - Research and development expenses for Q1 2025 were ¥37,729,451.82, an increase of 7.9% from ¥34,967,288.47 in Q1 2024[21]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 8,025[12]. - The company reported a total of 30,897,300 unrestricted circulating shares held by the largest shareholder, Li Qian[14]. - The number of shares held by the top ten unrestricted shareholders totaled 77,000,000, indicating a concentration of ownership[14]. - The company has not reported any significant changes in the participation of major shareholders in margin financing and securities lending activities[15]. - There are no significant reminders or additional important information regarding the company's operational performance during the reporting period[15]. Operational Challenges - The decline in net profit was mainly attributed to the impact of centralized procurement and the MAH system on the company's generic drug business, leading to decreased revenue and increased cost rates[10].